Repertoire of adhesion molecules on day 11 FL cells and BM HPCs
| Surface marker . | Adult BM CD34+ . | FL day 11 of gestation . | ||
|---|---|---|---|---|
| c-Kit+ CD34+ . | c-Kit+CD34− . | c-Kit+ . | ||
| L-selectin | 65.2 ± 2.5 | 11.6 ± 0.4‡ | 9.8 ± 2.0‡ | 8.2 ± 0.5‡ |
| (Mel-14) | (659 ± 88) | (269 ± 120) | (68 ± 13)† | (244 ± 18)* |
| CD44 | 92.2 ± 2.9 | 82.7 ± 5.7 | 95.7 ± 3.1 | 93.5 ± 0.8 |
| (IM7) | (1069 ± 246) | (1507 ± 38) | (967 ± 19) | (1158 ± 139) |
| CD11a | 71.3 ± 3.5 | 78.6 ± 5.4 | 80.1 ± 15.4 | 63.9 ± 9.4 |
| (2D7) | (462 ± 17) | (647 ± 137) | (348 ± 34) | (596 ± 131) |
| CD11b | 53.6 ± 14.5 | 58.5 ± 1.6 | 18.0 ± 4.2* | 27.3 ± 7.1 |
| (M1/70) | (1204 ± 294) | (730 ± 114) | (158 ± 31)† | (641 ± 139) |
| α4 | 54.0 ± 8.8 | 69.9 ± 4.7 | 99.4 ± 0.3† | 85.8 ± 1.7* |
| (R1-2) | (240 ± 26) | (447 ± 63)* | (599 ± 59)† | (535 ± 53)† |
| α5 | 57.5 ± 12.8 | 87.5 ± 7.7 | 97.6 ± 2.2* | 69.9 ± 11.9 |
| (5H10-27) | (333 ± 26) | (701 ± 26)‡ | (390 ± 138) | (570 ± 102) |
| α4β7 | 7.2 ± 2.6 | 2.2 ± 0.5 | 4.9 ± 2.3 | 0.8 ± 0.5 |
| (DATK 32) | (276 ± 43) | (309 ± 54) | (57 ± 14)* | (466 ± 84) |
| PSGL1 | 63.1 ± 3.5 | 49.9 ± 10.0 | 29.7 ± 8.6* | 36.3 ± 8.5* |
| (2PH1) | (794 ± 17) | (301 ± 26)‡ | (76 ± 14)‡ | (171 ± 22)‡ |
| Surface marker . | Adult BM CD34+ . | FL day 11 of gestation . | ||
|---|---|---|---|---|
| c-Kit+ CD34+ . | c-Kit+CD34− . | c-Kit+ . | ||
| L-selectin | 65.2 ± 2.5 | 11.6 ± 0.4‡ | 9.8 ± 2.0‡ | 8.2 ± 0.5‡ |
| (Mel-14) | (659 ± 88) | (269 ± 120) | (68 ± 13)† | (244 ± 18)* |
| CD44 | 92.2 ± 2.9 | 82.7 ± 5.7 | 95.7 ± 3.1 | 93.5 ± 0.8 |
| (IM7) | (1069 ± 246) | (1507 ± 38) | (967 ± 19) | (1158 ± 139) |
| CD11a | 71.3 ± 3.5 | 78.6 ± 5.4 | 80.1 ± 15.4 | 63.9 ± 9.4 |
| (2D7) | (462 ± 17) | (647 ± 137) | (348 ± 34) | (596 ± 131) |
| CD11b | 53.6 ± 14.5 | 58.5 ± 1.6 | 18.0 ± 4.2* | 27.3 ± 7.1 |
| (M1/70) | (1204 ± 294) | (730 ± 114) | (158 ± 31)† | (641 ± 139) |
| α4 | 54.0 ± 8.8 | 69.9 ± 4.7 | 99.4 ± 0.3† | 85.8 ± 1.7* |
| (R1-2) | (240 ± 26) | (447 ± 63)* | (599 ± 59)† | (535 ± 53)† |
| α5 | 57.5 ± 12.8 | 87.5 ± 7.7 | 97.6 ± 2.2* | 69.9 ± 11.9 |
| (5H10-27) | (333 ± 26) | (701 ± 26)‡ | (390 ± 138) | (570 ± 102) |
| α4β7 | 7.2 ± 2.6 | 2.2 ± 0.5 | 4.9 ± 2.3 | 0.8 ± 0.5 |
| (DATK 32) | (276 ± 43) | (309 ± 54) | (57 ± 14)* | (466 ± 84) |
| PSGL1 | 63.1 ± 3.5 | 49.9 ± 10.0 | 29.7 ± 8.6* | 36.3 ± 8.5* |
| (2PH1) | (794 ± 17) | (301 ± 26)‡ | (76 ± 14)‡ | (171 ± 22)‡ |
Cells were stained for HPC markers and adhesion molecules (names of mAbs used are shown in parentheses). Adult BM HPCs were defined as CD34+ cells and constituted 3% ± 1% of all BM cells. Day 11 FL HPC were defined as c-Kit+ (50% ± 3% of all day 11 FL cells) and were further subdivided into 2 groups: CD34+(9% ± 1%) and CD34− (41% ± 3%). Data are shown for both subsets individually and for all c-Kit+ cells. Results are shown as the mean percentage of marker-positive live cells. Numbers in parentheses represent mean fluorescence intensity. Data are shown as mean ± SEM of at least 3 independent experiments. For statistical comparison, results from FL HPCs were compared to BM-derived CD34+ HPCs.
P ≤ .05.
P ≤ .01.
P ≤ .005.